Remdesivir for the Treatment of Covid-19 — Preliminary Report

In the trial conducted by Beigel and colleagues, hospitalized patients who received remdesivir had a significantly shorter time to clinical recovery than those who received placebo (median recovery time, 11 days vs. 15 days). The median time from symptom onset to randomization was 9 days (interquartile range, 6 to 12). Notably, the benefit of remdesivir was limited to patients who received oxygen therapy; it did not extend to those with mild disease or those who were receiving advanced ventilation.

Remdesivir for the Treatment of Covid-19 — Preliminary Report
Size: 324 KB